Sunday, 22 July 2018 - 3:39
  • it
  • de
  • en
  • fr


Novo focuses on new obesity therapy Semaglutide

Novo Nordisk reiterated last week, during a presentation to investors and analysts, the importance of its new investigational obesity therapy semaglutide for its future. Novo recently completed a Phase II clinical trial with semaglutide vs Saxenda vs Placebo, enrolling 1,000…